LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. (LENZ) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · LENZ · as of Sep 30, 2025
Ownership Breakdown
171
Institutional Holders
▲ 54 vs Q2
$1.36B
Total Inst. Value
▲ $630.47M vs Q2
31.35M
Shares Outstanding
freeFloat 87.26%
29.14M
13F Shares Held
▲ 4.41M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
LENZ largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 4.18M | 14.88% | 14.88% | $194.65B | Nov 14, 2025 | — held |
ALPHA WAVE GLOBAL, LP biological products, (no diagnostic substances) | 3.61M | 12.86% | 12.86% | $168.26B | Nov 13, 2025 | — held |
VERSANT VENTURE MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.66M | 9.46% | 9.46% | $123.76B | Nov 10, 2025 | NEW |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.47M | 5.25% | 5.25% | $68.62B | Nov 12, 2025 | ▲ 40.6K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.33M | 4.74% | 4.74% | $61.96B | Nov 7, 2025 | ▲ 39.3K |
UBS GROUP AG biological products, (no diagnostic substances) | 1.20M | 4.28% | 4.28% | $55.97B | Nov 13, 2025 | ▲ 320.1K |
PARADIGM BIOCAPITAL ADVISORS LP biological products, (no diagnostic substances) | 1.07M | 3.82% | 3.82% | $50.00B | Nov 14, 2025 | ▼ 643.6K |
72 INVESTMENT HOLDINGS, LLC biological products, (no diagnostic substances) | 1.02M | 3.62% | 3.62% | $47.41B | Nov 14, 2025 | — held |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 897.6K | 3.20% | 3.20% | $41.81B | Nov 14, 2025 | — held |
RTW INVESTMENTS, LP biological products, (no diagnostic substances) | 863.4K | 3.07% | 3.07% | $40.22B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
28
Increased
+3.08M shares7
New Positions
first time holders7
Decreased
−1.90M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.18M
+3.08M / −1.90M
Net new holders
+28
7 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
LENZ insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
3
Sell transactions
1.33
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
George Jeffrey P. director | Mar 27, 2026 | Purchase | 5,592 | $8.92 | $49.9K | 5.6K | Form 4 ↗ |
Schimmelpennink Evert B. President, CEO and Secretary | Mar 27, 2026 | Purchase | 28,089 | $8.95 | $251.4K | 77.3K | Form 4 ↗ |
Chevallard Daniel R. Chief Financial Officer | Mar 27, 2026 | Purchase | 7,500 | $8.57 | $64.3K | 12.9K | Form 4 ↗ |
Olsson Shawn Chief Commercial Officer | Jan 2, 2026 | Award | 84,200 | $16.00 | $1.35M | 84.2K | Form 4 ↗ |
Odrich Marc Chief Medical Officer | Jan 2, 2026 | Award | 84,200 | $16.00 | $1.35M | 84.2K | Form 4 ↗ |
Chevallard Daniel R. Chief Financial Officer | Jan 2, 2026 | Award | 84,200 | $16.00 | $1.35M | 84.2K | Form 4 ↗ |
Schimmelpennink Evert B. President, CEO and Secretary | Jan 2, 2026 | Award | 358,100 | $16.00 | $5.73M | 358.1K | Form 4 ↗ |
Olsson Shawn Chief Commercial Officer | Nov 17, 2025 | Sale | 4,212 | $25.74 | $108.4K | 10.5K | Form 4 ↗ |
Olsson Shawn Chief Commercial Officer | Nov 17, 2025 | Sale | 5,788 | $26.37 | $152.6K | 4.7K | Form 4 ↗ |
MCCOLLUM JAMES W director | Nov 7, 2025 | Purchase | 10,500 | $22.79 | $239.3K | 10.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
LENZ Therapeutics, Inc. (LENZ) is primarily owned by institutional investors, who hold approximately 92.9% of total shares outstanding. Company insiders own approximately 12.74%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of LENZ Therapeutics, Inc. is RA CAPITAL MANAGEMENT, L.P., holding approximately 4.18 million shares — equal to 14.88% of outstanding shares — as of September 30, 2025.
A total of 171 institutional investors currently hold LENZ stock, with a combined institutional value of approximately $1.36 billion as of the most recent 13F filing period.
Frequently asked questions
LENZ ownershipLENZ Therapeutics, Inc. (LENZ) is primarily owned by institutional investors, who hold approximately 92.9% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 14.88% stake. Company insiders hold 12.74%. Data sourced from SEC Form 13F as of September 30, 2025.